Clinical Trial: A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973668) titled 'A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease' on May 06.

Brief Summary: The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.

Study Start Date: Oct. 01, 2025

Study Type: INTERVENTIONAL

Condition: AML

Intervention: DRUG: Mycophenolate Mofetil

15 mg/kg/dose (max: 1,000mg/dose) IV/PO three times daily ...